Kevin Johnson (born 30 August 1960 in

Holyhead Holyhead (,; cy, Caergybi , "Cybi's fort") is the largest town and a community in the county of Isle of Anglesey, Wales, with a population of 13,659 at the 2011 census. Holyhead is on Holy Island, bounded by the Irish Sea to the north, and is ...

, Wales) is a partner at medicxi, a venture capital firm focused on

life sciences This list of life sciences comprises the branches of science that involve the scientific study of life – such as microorganisms, plants, and animals including human beings. This science is one of the two major branches of natural science, the ...

investments based on the asset-centric approach to investing. He was formerly with Index Ventures, having joined the venture capital firm in 2010.

Education and career

Johnson graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University. From 1990 onwards, Johnson was one of the team at Cambridge Antibody Technology (CAT), heading up research and in 1997 he was appointed to the board, where he held the posts of Research Director and Chief Technology Officer. Kevin led both the development of CAT's platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development, including the first such drug, Humira to reach the market. He was also part of the management team that floated CAT on the London Stock Exchange (main market). Johnson was

CEO A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO) or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization especially ...

of PanGenetics before it was acquired by

Abbott Laboratories Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known dr ...

for $170 million in 2009. From 2004 to 2016, Johnson worked with Index Ventures' Life Sciences team, first as a venture advisor and then as a partner, and in 2016 co-founded medicxi with three other Index partners.

Index Ventures Portfolio Company Involvement

*Molecular Partners
PanGenetics
(acquired by Abbott Pharmaceuticals) *Versartis *Diartis Pharmaceuticals

Feature Articles

Index Appoints Johnson Partner

Related Awards

In 2010, Pangenetics was shortlisted for the Newsflow category at the Genesis 2010 Awards and for Management Team of the Year at the Scrip Awards.

External links

medicxi website

Index Ventures website

References

{{DEFAULTSORT:Johnson, Kevin 1960 births Living people British venture capitalists